Breaking News Instant updates and real-time market news.

CRBP

Corbus Pharmaceuticals

$7.02

0.15 (2.18%)

12:50
10/05/16
10/05
12:50
10/05/16
12:50

Corbus soars after analyst says buy ahead of data, eyes potential double

Clinical-stage drug developer Corbus Pharmaceuticals (CRBP) soared Wednesday after research firm Cantor Fitzgerald started coverage of the stock with a $17 price target -- more than double its $7 closing price on Tuesday -- on the firm's conviction in upcoming results for the company's anti-inflammatory therapy Resunab. CANTOR SEES MULTIPLE INFLECTION POINTS: Cantor Fitzgerald analyst Elemer Piros initiated coverage of Corbus with a Buy rating and $17 price target. Piros sees the inflammation and fibrosis researcher achieving three inflection points over the next year, beginning with data presentations in November on its lead candidate Resunab. In pre-clinical models, the drug showed an encouraging ability to restore the body's anti-inflammatory processes, and Corbus is set to unveil initial efficacy results in diffuse cutaneous systemic sclerosis in November, cystic fibrosis in January, and dermatomyositis in the second half of 2017. Piros also notes that Corbus has filed patents for an ultrapure formulation of Resunab that could extend patent protection until 2033. The analyst estimates a $3B combined market potential for the three orphan indications, and he models their risk-adjusted present value at more than $700M, yielding his $17 twelve-month price target. PRICE ACTION: Shares of Corbus Pharmaceuticals have soared 30% to $9.11. Year-to-date the stock, which closed at $1.61 per share on January 4, has advanced by about 450%.

CRBP Corbus Pharmaceuticals
$7.02

0.15 (2.18%)

09/19/16
AGIS
09/19/16
NO CHANGE
Target $12
AGIS
Buy
Corbus Pharmaceuticals price target raised to $12 from $7 at Aegis
Aegis analyst Robert Leboyer raised his price target for Corbus Pharmaceuticals to $12 from $7 and keeps a Buy rating on the name.
10/04/16
CANT
10/04/16
INITIATION
Target $17
CANT
Buy
Corbus Pharmaceuticals initiated with a Buy at Cantor
Cantor initiated Corbus Pharmaceuticals with a Buy and a $17 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.